Sun exposure is the most important risk factor of cutaneous melanoma, but several studies have suggested that some prescripted drugs also may play a part. This project aims to investigaste if prescripted drugs influence the risk of, and death due to cutaneous melanoma and provide better and more targeted prevention of cutaneous melanoma through the identification of high-risk persons.
Cutaneous Malignant Melanoma is largely caused by exposure to ultraviolet radiation (UVR). UVR is also our main source of vitamin D,which have been associated with reduced risk of some cancers. The situation for melanoma is unclear, as both low and high vitamin D levels have been associated with increased risk.
Presence of certain bacteria in the gut are strongly associated with colorectal cancer. It is now possible to investigate all bacteria in the gut, - the microbiota, for its role in initiation and progression of colorectal cancer. This project is a sub-study within the Bowel Cancer Screening in Norway (BCSN) trial that aims to discover gut microbiota biomarkers for colorectal cancer screening.
Medications can affect cancer risk; menopausal hormone therapy can for instance influence the risk of breast and ovarian cancer. The aim of the project is to study associations between medication use and the risk of cancer and prognosis after a cancer diagnosis.
HPV-SEQ is an cross-institutional research group with the main goals: 1) To discover HPV biomarkers 2) To delineate HPV evolution 3) To develop HPV detection and characterization methods. We take advantage of Next Generation Sequencing (NGS) Technology to reach our goals.
Small noncoding RNAs (sncRNA) are involved in numerous cellulary processes in cancer development. We are currently investigating sncRNA as early detection and potential screening biomarkers of cancer.
NORCCAP (Norwegian Colorectal Cancer Prevention) is a randomized study on screening for colorectal cancer (CRC) and adenomatous polyps (potential precursor lesions for colorectal cancer). The project arose from an initiative made by the Norwegian Gastrointestinal Cancer Group (NGICG) and the Norwegian Cancer Society with funding from the Norwegian Cancer Society and the Ministry of Health and Social Affairs.